Aliases & Classifications for Oppositional Defiant Disorder

MalaCards integrated aliases for Oppositional Defiant Disorder:

Name: Oppositional Defiant Disorder 12 73 54 6 15 70 32


External Ids:

Disease Ontology 12 DOID:0050856
ICD10 32 F91.3
UMLS 70 C0029121

Summaries for Oppositional Defiant Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by a pattern of angry mood, defiant behavior and vindictiveness in children and adolescents.

MalaCards based summary : Oppositional Defiant Disorder is related to conduct disorder and depression, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Oppositional Defiant Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Neurotransmitter Agents and Atomoxetine Hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include eye, cortex and amygdala, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Oppositional defiant disorder (ODD) is listed in the DSM-5 under Disruptive, impulse-control, and... more...

Related Diseases for Oppositional Defiant Disorder

Diseases related to Oppositional Defiant Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 conduct disorder 30.7 SLC6A4 SLC6A3 OXTR MAOA GABRA2 DRD5
2 depression 30.6 TPH2 SLC6A4 MAOA HTR2A
3 generalized anxiety disorder 30.6 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A DRD2
4 stuttering 30.5 SLC6A3 DRD2 DBH
5 adjustment disorder 30.4 SLC6A4 OXT HTR2A
6 traumatic brain injury 30.4 DRD2 COMT ANKK1
7 sleep disorder 30.4 SLC6A4 SLC6A3 HTR2A COMT
8 mood disorder 30.3 TPH2 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A
9 phobia, specific 30.2 SLC6A4 OXT MAOA HTR2A COMT
10 separation anxiety disorder 30.0 SLC6A4 SLC6A3 OXTR OXT MAOA DRD4
11 dysthymic disorder 30.0 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A DRD4
12 borderline personality disorder 29.9 TPH2 SLC6A4 SLC6A3 OXTR MAOA HTR2A
13 post-traumatic stress disorder 29.7 SLC6A4 OXTR MAOA HTR2A DRD2 DBH
14 anxiety 29.5 TPH2 SLC6A4 SLC6A3 SLC6A2 OXTR OXT
15 substance dependence 29.5 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
16 tic disorder 29.4 TPH2 SLC6A4 SLC6A3 MAOA HTR2A DRD4
17 personality disorder 29.4 TPH2 SNAP25 SLC6A4 SLC6A3 OXTR MAOA
18 substance abuse 29.3 SLC6A4 SLC6A3 MAOA HTR2A GABRA2 DRD5
19 mental depression 29.0 TPH2 SLC6A4 SLC6A3 SLC6A2 OXTR OXT
20 attention deficit-hyperactivity disorder 28.9 TPH2 SNAP25 SLC6A4 SLC6A3 SLC6A2 OXT
21 antisocial personality disorder 28.8 SNAP25 SLC6A4 SLC6A3 OXTR OXT MAOA
22 alcohol use disorder 28.8 SLC6A4 SLC6A3 HTR2A GABRA2 DRD2 DRD1
23 bipolar disorder 28.5 TPH2 SNAP25 SLC6A4 SLC6A3 SLC6A2 MAOA
24 gilles de la tourette syndrome 28.4 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A DRD5
25 major depressive disorder 28.3 TPH2 SLC6A4 SLC6A3 SLC6A2 OXTR OXT
26 autism 28.0 TPH2 SNAP25 SLC6A4 SLC6A3 SLC6A2 OXTR
27 alcohol dependence 28.0 TPH2 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A
28 autism spectrum disorder 27.6 TPH2 SNAP25 SLC6A4 SLC6A3 SLC6A2 OXTR
29 schizophrenia 26.5 TPH2 SNAP25 SLC6A4 SLC6A3 SLC6A2 OXTR
30 disease of mental health 26.0 TPH2 SNAP25 SLC6A4 SLC6A3 SLC6A2 OXTR
31 major affective disorder 8 10.6
32 major affective disorder 9 10.6
33 pseudobulbar affect 10.5
34 dependent personality disorder 10.4 MAOA DRD4
35 exhibitionism 10.3 MAOA DRD4
36 alcohol-induced mental disorder 10.3 SLC6A4 DRD2
37 polysubstance abuse 10.3 DRD2 COMT
38 barbiturate dependence 10.3 SLC6A4 DBH
39 narcissistic personality disorder 10.3 OXT MAOA
40 amphetamine abuse 10.3 SLC6A4 SLC6A3 SLC6A2
41 drug psychosis 10.3 SLC6A3 DRD2 COMT
42 drug-induced mental disorder 10.3 SLC6A3 DRD2 COMT
43 animal phobia 10.3 SLC6A4 OXT
44 brunner syndrome 10.2 SLC6A4 MAOA COMT
45 inhibited male orgasm 10.2 SLC6A4 SLC6A3 OXT
46 flying phobia 10.2 OXT MAOA COMT
47 sexual sadism 10.2 OXT MAOA COMT
48 alcoholic psychosis 10.2 SLC6A4 SLC6A3 HTR2A
49 somatization disorder 10.2 SLC6A4 OXT COMT
50 multiple system atrophy 1 10.2 SLC6A3 DRD2 DBH

Graphical network of the top 20 diseases related to Oppositional Defiant Disorder:

Diseases related to Oppositional Defiant Disorder

Symptoms & Phenotypes for Oppositional Defiant Disorder

UMLS symptoms related to Oppositional Defiant Disorder:

photophobia; restlessness; personality changes; pseudobulbar behavioral symptoms; sleep disturbances

GenomeRNAi Phenotypes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.66 MAOA
2 Decreased viability GR00173-A 9.66 ANKK1
3 Decreased viability GR00221-A-1 9.66 GABRA2
4 Decreased viability GR00221-A-2 9.66 ANKK1 GABRA2
5 Decreased viability GR00221-A-4 9.66 ANKK1 GABRA2
6 Decreased viability GR00240-S-1 9.66 COMT
7 Decreased viability GR00249-S 9.66 COMT NIPA2 SLC6A2 SLC6A4
8 Decreased viability GR00381-A-1 9.66 SLC6A4
9 Decreased viability GR00381-A-3 9.66 SLC6A4
10 Decreased viability GR00386-A-1 9.66 COMT DBH DRD1 NIPA2 SLC6A2 TPH2
11 Decreased viability GR00402-S-2 9.66 OXTR TPH2

MGI Mouse Phenotypes related to Oppositional Defiant Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 ADRA2A COMT DBH DRD1 DRD2 DRD4
2 cardiovascular system MP:0005385 10.22 ADRA2A COMT DBH DRD1 DRD2 DRD5
3 homeostasis/metabolism MP:0005376 10.17 ADRA2A COMT DBH DRD1 DRD2 DRD4
4 endocrine/exocrine gland MP:0005379 10.15 ADRA2A COMT DBH DRD2 DRD5 HTR2A
5 nervous system MP:0003631 10.06 ADRA2A COMT DBH DRD1 DRD2 DRD4
6 integument MP:0010771 10.03 DBH DRD1 DRD2 GABRA2 NET1 OXT
7 adipose tissue MP:0005375 10 DBH DRD1 DRD2 NET1 OXT SNAP25
8 normal MP:0002873 9.65 ADRA2A DBH DRD1 DRD2 DRD5 OXTR
9 taste/olfaction MP:0005394 8.92 DRD2 SLC6A3 SNAP25 TPH2

Drugs & Therapeutics for Oppositional Defiant Disorder

Drugs for Oppositional Defiant Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Neurotransmitter Agents Phase 4
2 Atomoxetine Hydrochloride Phase 4
3 Adrenergic Agents Phase 4
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
6 Psychotropic Drugs Phase 3
7 Dopamine Antagonists Phase 3
8 Dopamine Agents Phase 3
9 Antipsychotic Agents Phase 3
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
11 Hormones

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder Completed NCT00406354 Phase 4 Atomoxetine;Placebo
2 The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Completed NCT00266552 Phase 3 risperidone
3 An Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder Completed NCT00192023 Phase 3 atomoxetine 0.5 mg/kg/day;placebo;atomoxetine 1.2 mg/kg/day;atomoxetine 1.2-1.4 mg/kg/day
4 A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder Completed NCT00191698 Phase 3 atomoxetine hydrochloride;placebo
5 Treatment of Children With Peer Related Aggressive Behavior With the Treatment Programme THAV - a Randomized Controlled Trial Completed NCT01406067 Phase 3
6 Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children Completed NCT00399698 Phase 3 Risperdal
7 Delivering Intervention for Pediatric Behaviour Problems at a Distance: a Randomized Trial of Strongest Families Ontario Completed NCT01473511 Phase 3
8 Parent Management Training to Prevent Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189
9 Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions Unknown status NCT02409992
10 Efficacy of Cognitive-Behavioral Based Guided Self-Help for Parents of Children With Externalizing Problem Behavior Unknown status NCT01350986
11 Treatment of Children With Peer Related Aggressive Behavior With the Computer Based Treatment Program ScouT - a Randomized Controlled Trial Unknown status NCT02143427
12 Observational Study on Intrafamilial Oppositional Defiant Disorder (IODD) in Children and Adolescents Completed NCT03447535
13 Mediators, Moderators, and Treatment Outcomes With ODD Youth Completed NCT00510120
14 Enhancing Long-Term Outcome in Child Behavior Disorders Completed NCT00820001
15 Family Groups to Reduce Youth Behavioral Difficulties Completed NCT00404911
16 Evaluating the Feasibility of Internet-delivered Parent-Child Interaction Therapy Completed NCT03260725
17 Virtual Reality to Improve Social Perspective Taking in Youth With Disruptive Behavior Disorders Recruiting NCT03927612
18 Randomized Control Trial of Regulation Focused Psychotherapy for Children (RFP-C) With Externalizing Behaviors Active, not recruiting NCT03594253
19 Parent Training Targeting Externalizing Behaviors in Children in Primary Care: A Randomized Non-inferiority Study of the Comet-program Delivered Via the Internet or in Group Format. Active, not recruiting NCT03465384
20 Preschool First Step to Success: An Efficacy Replication Study Enrolling by invitation NCT03729154

Search NIH Clinical Center for Oppositional Defiant Disorder

Genetic Tests for Oppositional Defiant Disorder

Anatomical Context for Oppositional Defiant Disorder

MalaCards organs/tissues related to Oppositional Defiant Disorder:

Eye, Cortex, Amygdala, Pituitary, Brain, Placenta, Thyroid

Publications for Oppositional Defiant Disorder

Articles related to Oppositional Defiant Disorder:

(show top 50) (show all 2027)
# Title Authors PMID Year
Association of dopamine transporter genotype with disruptive behavior disorders in an eight-year longitudinal study of children and adolescents. 54 61
17192955 2007
Phenotype studies of the DRD4 gene polymorphisms in ADHD: association with oppositional defiant disorder and positive family history. 54 61
15389763 2004
Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. 61 54
15801334 2004
Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes--DRD2, D beta H, and DAT1. 61 54
8725745 1996
The role of tryptophan metabolic pathway in children with attention deficit hyperactivity disorder with and without comorbid oppositional defiant disorder and conduct disorder. 61
33545424 2021
Research review: A meta-analysis of the international prevalence and comorbidity of mental disorders in children between 1 and 7 years. 61
32433792 2021
Impulsive States and Impulsive Traits: A Study of the Multilevel Structure and Validity of a Multifaceted Measure of Impulsive States. 61
32680433 2021
Validity of Sluggish Cognitive Tempo in Turkish Children and Adolescents. 61
33432461 2021
Trajectories of Response to Treatments in Children with ADHD and Word Reading Difficulties. 61
33772416 2021
Sluggish Cognitive Tempo and ADHD Symptoms in a Nationally Representative Sample of U.S. Children: Differentiation Using Categorical and Dimensional Approaches. 61
31671271 2021
A latent profile analysis of borderline personality features and externalizing problems in youth. 61
32886825 2021
Quantitative EEG in Childhood Attention Deficit Hyperactivity Disorder and Learning Disabilities. 61
33012168 2021
Oral health status and oral health-related quality of life in children with attention-deficit hyperactivity disorder and oppositional defiant disorder. 61
33421188 2021
Interactive association of maternal education and peer relationship with oppositional defiant disorder: an observational study. 61
33752611 2021
Poly-victimization and psychopathological symptoms in adolescence: Examining the potential buffering effect of positive childhood experiences. 61
33601709 2021
Assessing Callous-Unemotional Traits in 6- to 18-Year-Olds: Reliability, Validity, Factor Structure, and Norms of the German Version of the Inventory of Callous-Unemotional Traits. 61
31096770 2021
Toward a Developmental Nosology for Disruptive Mood Dysregulation Disorder in Early Childhood. 61
32599006 2021
Diagnostic classification of irritability and oppositionality in youth: a global field study comparing ICD-11 with ICD-10 and DSM-5. 61
32396664 2021
Maltreatment and Affective and Behavioral Problems in Emerging Adults With and Without Oppositional Defiant Disorder Symptoms: Mediation by Parent-Child Relationship Quality. 61
29528803 2021
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment. 61
32497602 2021
Intervention response among preschoolers with ADHD: The role of emotion understanding. 61
33581768 2021
Psychometric Properties and Normative Information on the Child and Adolescent Behavior Inventory with Ratings for Spanish Children from Parents and Teachers. 61
33453747 2021
Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH. 61
33583471 2021
Investigating the Measurement Invariance and Method-Trait Effects of Parent and Teacher SNAP-IV Ratings of Preschool Children. 61
33638743 2021
Cognitive behavior therapy for externalizing disorders in children and adolescents in routine clinical care: A systematic review and meta-analysis. 61
33418192 2021
External validation of a bifactor model of oppositional defiant disorder. 61
30538308 2021
Validity of DSM-5 Oppositional Defiant Disorder Symptoms in Children with Intellectual Disability. 61
33670742 2021
Psychiatric comorbidity and social adjustment difficulties in children with disruptive mood dysregulation disorder: A national epidemiological study. 61
33383391 2021
ROC Analyses of Relevant Conners 3-Short Forms, CBCL, and TRF Scales for Screening ADHD and ODD. 61
31535569 2021
Psychometric and Normative Information on the Child and Adolescent Behavior Inventory in a Nationally Representative Sample of United States Children. 61
33428463 2021
Psychiatric comorbidities of children with elimination disorders. 61
33223199 2021
The Factor Structure and Gender Invariance of ADHD Symptoms in College Students. 61
32452694 2021
Evaluation of psychiatric comorbidity in attention-deficit hyperactivity disorder with epilepsy: A case-control study. 61
33302225 2021
Inhibitory Control Deficits in Children with Oppositional Defiant Disorder and Conduct Disorder Compared to Attention Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. 61
33048265 2021
The Use of Indirect Aggression among Boys and Girls with and without Conduct Problems: Trajectories from Childhood to Adolescence. 61
32990825 2021
The significance of limited prosocial emotions among externalizing disorders in children. 61
33389151 2021
The Role of Perspective Taking and Self-Control in a Preventive Intervention Targeting Childhood Disruptive Behavior. 61
33439419 2021
Incidence and comorbidities of disruptive behavior disorders diagnosed in Finnish specialist psychiatric services. 61
33398496 2021
Impulsivity as Early Emerging Vulnerability Factor-Prediction of ADHD by a Preschool Neuropsychological Measure. 61
33418940 2021
Friendly Faces: Characteristics of Children and Adolescents With Repeat Visits to a Specialized Child Psychiatric Emergency Program. 61
29438124 2021
Long-Term Effectiveness of Guided Self-Help for Parents of Children With ADHD in Routine Care-An Observational Study. 61
30449268 2021
Parenting styles for children with oppositional defiant disorder: Scope review. 61
33688530 2021
The Main and Interactive Associations between Demographic Factors and Psychopathology and Treatment Utilization in Youth: A Test of Intersectionality in the ABCD Study. 61
32737734 2021
A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. 61
33395356 2020
Clinical Subtypes in Children with Attention-Deficit Hyperactivity Disorder According to Their Child Behavior Checklist Profile. 61
32166459 2020
Association between lack of functional connectivity of the frontal brain region and poor response inhibition in children with frontal lobe epilepsy. 61
33232894 2020
Psychiatric Comorbidity in the Subtypes of ADHD in Children and Adolescents with ADHD According to DSM-IV. 61
33354119 2020
Editorial: A Transdiagnostic Symptom Requires a Transdiagnostic Approach: Neural Mechanisms of Pediatric Irritability. 61
32966839 2020
Neural Correlates of Adolescent Irritability and Its Comorbidity With Psychiatric Disorders. 61
32860907 2020
Treatment Response among Preschoolers with Disruptive Behavior Disorders: The Role of Temperament and Parenting. 61
33275456 2020

Variations for Oppositional Defiant Disorder

ClinVar genetic disease variations for Oppositional Defiant Disorder:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 14 genes GRCh37/hg19 22q11.21(chr22:20728956-21465662)x3 copy number gain Uncertain significance 692091 GRCh37: 22:20728956-21465662

Expression for Oppositional Defiant Disorder

Search GEO for disease gene expression data for Oppositional Defiant Disorder.

Pathways for Oppositional Defiant Disorder

Pathways related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
4 12.27 OXTR HTR2A DRD5 DRD1
5 12.23 DRD5 DRD4 DRD2 DRD1
Show member pathways
11.96 SNAP25 SLC6A4 SLC6A3 SLC6A2
Show member pathways
11 11.89 TPH2 SLC6A4 MAOA HTR2A
Show member pathways
11.85 SLC6A4 SLC6A2 COMT
Show member pathways
11.84 DRD4 DRD2 DRD1
Show member pathways
11.79 SNAP25 DRD4 DRD2
15 11.72 HTR2A DRD2 DRD1
Show member pathways
Show member pathways
18 11.07 TPH2 SLC6A4 MAOA HTR2A
Show member pathways
20 11.05 SLC6A2 DBH ADRA2A
Show member pathways
Show member pathways
23 10.91 SNAP25 DRD2 ANKK1
Show member pathways
Show member pathways
26 10.75 MAOA COMT

GO Terms for Oppositional Defiant Disorder

Cellular components related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.43 SNAP25 SLC6A4 SLC6A3 SLC6A2 OXTR NIPA2
2 plasma membrane GO:0005886 10.32 SNAP25 SLC6A4 SLC6A3 SLC6A2 OXTR NIPA2
3 integral component of membrane GO:0016021 10.28 SLC6A4 SLC6A3 SLC6A2 OXTR NIPA2 MAOA
4 dendrite GO:0030425 9.93 HTR2A GABRA2 DRD4 DRD2 DRD1 COMT
5 neuron projection GO:0043005 9.91 TPH2 SNAP25 SLC6A4 SLC6A3 SLC6A2 GABRA2
6 synapse GO:0045202 9.86 SNAP25 SLC6A4 HTR2A GABRA2 DRD5 DRD2
7 axon GO:0030424 9.85 SNAP25 SLC6A3 HTR2A GABRA2 DRD2 COMT
8 presynaptic membrane GO:0042734 9.71 SNAP25 SLC6A3 SLC6A2
9 ciliary membrane GO:0060170 9.69 DRD5 DRD2 DRD1
10 non-motile cilium GO:0097730 9.67 DRD5 DRD2 DRD1
11 integral component of presynaptic membrane GO:0099056 9.62 SLC6A4 SLC6A3 HTR2A DRD2
12 integral component of postsynaptic membrane GO:0099055 9.46 SLC6A4 SLC6A3 HTR2A DRD2
13 integral component of plasma membrane GO:0005887 9.36 SLC6A4 SLC6A3 SLC6A2 OXTR HTR2A GABRA2
14 dopaminergic synapse GO:0098691 9.13 SLC6A3 DRD2 ADRA2A

Biological processes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 OXTR OXT NET1 HTR2A GABRA2 DRD5
2 G protein-coupled receptor signaling pathway GO:0007186 10.25 OXTR OXT NET1 HTR2A DRD5 DRD4
3 response to organic cyclic compound GO:0014070 9.96 SLC6A3 OXTR OXT COMT
4 cellular calcium ion homeostasis GO:0006874 9.94 HTR2A DRD5 DRD4 DRD2
5 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.92 DRD5 DRD1 ADRA2A
6 response to estradiol GO:0032355 9.92 SLC6A4 OXTR OXT
7 locomotory behavior GO:0007626 9.92 SNAP25 SLC6A3 DRD2 DBH
8 sodium ion transmembrane transport GO:0035725 9.91 SLC6A4 SLC6A3 SLC6A2
9 positive regulation of cold-induced thermogenesis GO:0120162 9.91 OXTR OXT DBH
10 female pregnancy GO:0007565 9.91 OXTR OXT COMT
11 chemical synaptic transmission GO:0007268 9.91 SNAP25 SLC6A2 HTR2A GABRA2 DRD5 DRD4
12 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 HTR2A DRD4 DRD1
13 social behavior GO:0035176 9.88 SLC6A4 OXTR OXT DRD4
14 memory GO:0007613 9.88 SLC6A4 OXTR OXT HTR2A DBH
15 neurotransmitter transport GO:0006836 9.87 SLC6A4 SLC6A3 SLC6A2 GABRA2
16 regulation of synaptic vesicle exocytosis GO:2000300 9.85 HTR2A DRD2 ADRA2A
17 visual learning GO:0008542 9.85 DRD2 DRD1 DBH
18 associative learning GO:0008306 9.83 SNAP25 DRD5 DRD2 DBH
19 positive regulation of vasoconstriction GO:0045907 9.82 OXTR HTR2A DBH
20 negative regulation of blood pressure GO:0045776 9.81 OXT DRD5 DRD2
21 response to pain GO:0048265 9.79 SLC6A2 DBH COMT
22 behavioral response to cocaine GO:0048148 9.79 HTR2A DRD4 DRD2
23 prepulse inhibition GO:0060134 9.78 SLC6A3 DRD2 DRD1
24 maternal behavior GO:0042711 9.77 OXTR OXT DBH
25 sleep GO:0030431 9.76 OXTR OXT HTR2A
26 dopamine receptor signaling pathway GO:0007212 9.76 DRD5 DRD4 DRD2 DRD1
27 transmission of nerve impulse GO:0019226 9.74 DRD5 DRD1
28 response to iron ion GO:0010039 9.74 SLC6A3 DRD2
29 neurotransmitter biosynthetic process GO:0042136 9.74 SLC6A4 SLC6A3
30 positive regulation of renal sodium excretion GO:0035815 9.73 OXT DRD2
31 catecholamine metabolic process GO:0006584 9.73 MAOA COMT
32 grooming behavior GO:0007625 9.73 OXT DRD2
33 neurotransmitter uptake GO:0001504 9.73 SNAP25 SLC6A3
34 neurotransmitter catabolic process GO:0042135 9.73 MAOA COMT
35 monoamine transport GO:0015844 9.73 SLC6A4 SLC6A3 SLC6A2
36 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.73 DRD5 DRD2 DRD1 ADRA2A
37 negative regulation of voltage-gated calcium channel activity GO:1901386 9.72 DRD4 DRD2
38 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.72 HTR2A DRD2
39 positive regulation of potassium ion transport GO:0043268 9.72 DRD1 ADRA2A
40 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.72 DRD5 DRD1
41 regulation of dopamine metabolic process GO:0042053 9.72 SLC6A3 DRD4
42 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.72 DRD5 DRD2 DRD1
43 neurotransmitter reuptake GO:0098810 9.71 SLC6A4 SLC6A2
44 adenohypophysis development GO:0021984 9.71 SLC6A3 DRD2
45 mating behavior GO:0007617 9.71 DRD5 DRD1
46 hyaloid vascular plexus regression GO:1990384 9.71 SLC6A3 DRD2
47 behavioral response to ethanol GO:0048149 9.71 DRD4 DRD2 DBH
48 dopamine metabolic process GO:0042417 9.71 DRD4 DRD2 DRD1 COMT
49 cellular response to catecholamine stimulus GO:0071870 9.7 DRD5 DRD1
50 positive regulation of uterine smooth muscle contraction GO:0070474 9.7 OXTR OXT

Molecular functions related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 OXTR HTR2A DRD5 DRD4 DRD2 DRD1
2 symporter activity GO:0015293 9.71 SLC6A4 SLC6A3 SLC6A2
3 neurotransmitter receptor activity GO:0030594 9.69 HTR2A GABRA2 DRD4
4 serotonin binding GO:0051378 9.52 SLC6A4 HTR2A
5 epinephrine binding GO:0051379 9.49 DRD4 ADRA2A
6 norepinephrine binding GO:0051380 9.48 DRD4 ADRA2A
7 dopamine:sodium symporter activity GO:0005330 9.46 SLC6A3 SLC6A2
8 norepinephrine:sodium symporter activity GO:0005334 9.43 SLC6A3 SLC6A2
9 neurotransmitter transporter activity GO:0005326 9.43 SLC6A4 SLC6A3 SLC6A2
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD4 DRD2
11 monoamine transmembrane transporter activity GO:0008504 9.33 SLC6A4 SLC6A3 SLC6A2
12 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.32 DRD5 DRD1
13 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD5 DRD4 DRD2 DRD1
14 dopamine binding GO:0035240 9.02 SLC6A3 DRD5 DRD4 DRD2 DRD1

Sources for Oppositional Defiant Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....